Quest for the right Drug
קספו 8 מ"ג / 2 מ"ל זריקות XEFO 8 MG/2 ML INJECTION (LORNOXICAM)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
תוך-ורידי, תוך-שרירי : I.V, I.M
צורת מינון:
אבקה להכנת תמיסה לזריקה : POWDER FOR SOLUTION FOR INJECTION
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Adverse reactions : תופעות לוואי
4.8. Undesirable effects The most commonly observed adverse events of NSAIDs are gastrointestinal in nature. Peptic ulcers, perforation or GI bleeding, sometimes fatal, particularly in the elderly, may occur (see section 4.4). Nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melaena, haematemesis, ulcerative stomatitis, exacerbation of colitis and Crohn’s disease (see section 4.4) have been reported following administration of NSAIDs. Less frequently, gastritis has been observed. Approximately 20% of patients treated with lornoxicam can be expected to experience adverse reactions. The most frequent adverse effects of lornoxicam include nausea, dyspepsia, indigestion, abdominal pain, vomiting, and diarrhoea. These symptoms have generally occurred in less than 10% of patients in available studies. Oedema, hypertension, and cardiac failure, have been reported in association with NSAID treatment. Clinical trial and epidemiological data suggest that use of some NSAIDs (particularly at high doses and in long term treatment) may be associated with an increased risk of arterial thrombotic events (for example myocardial infarction or stroke) (see section 4.4). Exceptionally, occurrence of serious cutaneous and soft tissues infectious complications during varicella. Listed below in table 1 are undesirable effects which generally occurred in more than 0.05% of the 6.417 patients treated in clinical phase II, III and IV trials. The following convention is used for the classification of the frequency of an adverse drug reaction: Very common (≥1/10); Common (≥1/100, <1/10); Uncommon (≥1/1000, <1/100); rare (≥1/10.000, <1/1.000); Very rare (<1/10.000), not known (cannot be estimated from the available data) Table 1: Adverse effects System organ class Frequency Adverse reaction(s) Infections and infestations Rare Pharyngitis Blood and lymphatic Rare Anaemia, thrombocytopenia, leucopenia, prolonged system disorders bleeding time Very rare Ecchymosis. NSAIDs have been reported to cause potentially severe haematological disorders like neutropenia, agranulocytosis, aplastic anaemia, and haemolytic anaemia as class effects Immune system disorders Rare Hypersensitivity including anaphylactoid reactions and anaphylaxis Metabolism and nutrition Uncommon Anorexia, weight changes disorders Psychiatric disorders Uncommon Insomnia, depression Rare Confusion, nervousness, agitation Nervous system disorders Common Mild and transient headache, dizziness Rare Somnolence, paraesthesia, dysgeusia, tremor, migraine Very rare Aseptic meningitis in patients with SLE and mixed connective tissue disorder (see section 4.4) Eye disorders Common Conjunctivitis Rare Visual disturbances Ear and labyrinth Uncommon Vertigo, tinnitus disorders Cardiac disorders Uncommon Palpitations, tachycardia, oedema, cardiac failure (see section 4.4) Vascular disorders Uncommon Flushing, oedema Rare Hypertension, hot flush, haemorrhage, haematoma Respiratory, thoracic and Uncommon Rhinitis mediastinal disorders Rare Dyspnoea, cough, bronchospasm System organ class Frequency Adverse reaction(s) Gastrointestinal disorders Common Nausea, abdominal pain, dyspepsia, diarrhoea, vomiting Uncommon Constipation, flatulence, eructation, dry mouth, gastritis, gastric ulcer, upper abdominal pain, duodenal ulcer, mouth ulceration Rare Melaena, haematemesis, stomatitis, oesophagitis, gastrooesophageal reflux, dysphagia, aphthous stomatitis, glossitis, perforated peptic ulcer, gastrointestinal haemorrhage Hepatobiliary disorders Uncommon Increase in liver function tests, SGPT (ALT) or SGOT (AST) Very rare Hepatotoxicity resulting in e.g. hepatic failure, hepatitis, jaundice and cholestasis Skin and subcutaneous Uncommon Rash, pruritus, hyperhidrosis, rash erythematous, tissue disorders urticaria, angioedema, alopecia Rare Dermatitis, eczema, purpura Very rare Oedema and bullous reactions, Stevens-Johnson syndrome, toxic epidermal necrolysis Musculoskeletal and Uncommon Arthralgia connective tissue Rare Bone pain, muscle spasms, myalgia disorders Renal and urinary Rare Nocturia, micturition disorders, increase in blood urea disorders nitrogen and creatinine levels Very rare Lornoxicam may precipitate acute renal failure in patients with pre-existing renal impairment, who are dependent on renal prostaglandins for maintenance of renal blood flow (see section 4.4). Nephrotoxicity in various forms including nephritis and nephrotic syndrome has been associated with NSAIDs as class effect General disorders and Uncommon Malaise, face oedema administration site Rare Asthenia conditions Reporting of suspected adverse reactions: Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form: https://sideeffects.health.gov.il/
שימוש לפי פנקס קופ''ח כללית 1994
לא צוין
תאריך הכללה מקורי בסל
לא צוין
הגבלות
לא צוין
מידע נוסף